— Know what they know.
Not Investment Advice

AKTX NASDAQ

Akari Therapeutics, Plc
1W: -10.7% 1M: -14.1% 3M: -20.0% YTD: -24.8% 1Y: -77.8% 3Y: -94.6% 5Y: -99.4%
$8.72
-0.12 (-1.36%)
 
Weekly Expected Move ±9.3%
$7 $8 $9 $10 $10
NASDAQ · Healthcare · Biotechnology · Tech Score Sell · Power 29 · $10.0M mcap · 543679 float · 104.29% daily turnover · Short 48% of daily vol

Balance Sheet Trends

Total Assets
$48M -5.3% ▼
5Y CAGR: +26.8%
Total Liabilities
$20M -30.9% ▼
5Y CAGR: +30.2%
Shareholders Equity
$28M +27.4% ▲
5Y CAGR: +24.7%
Cash & Investments
$5M +100.2% ▲
5Y CAGR: -18.0%
Total Debt
$754K -76.9% ▼
Net Debt
-$4M -773.1% ▼

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$9M$13M$4M$3M$5M
Short-Term Investments$0$0$0$0$0
Cash & ST Investments$9M$13M$4M$3M$5M
Net Receivables$0$0$0$201K$0
Inventory$0$0$0$0$0
Other Current Assets$90K$100K$197K$60K$259K
Total Current Assets$12M$14M$4M$3M$5M
Property, Plant & Equip.$0$0$0$0$0
Goodwill & Intangibles$23K$17K$14K$48M$42M
Long-Term Investments$0$0$0$0$0
Other Non-Current Assets$0$0$0$0$0
Total Non-Current Assets$23K$17K$14K$48M$42M
Total Assets$12M$14M$4M$51M$48M
— Liabilities —
Accounts Payable$2M$947K$2M$12M$9M
Short-Term Debt$0$0$0$3M$754K
Deferred Revenue$0$0$0$0$0
Other Current Liabilities$1M$8M$3M$2M$12M
Total Current Liabilities$6M$12M$5M$20M$12M
Long-Term Debt$0$0$0$0$0
Other Non-Current Liab.$0$0$0$383K$261K
Total Non-Current Liabilities$0$0$0$8M$7M
Total Liabilities$6M$12M$5M$28M$20M
— Equity —
Common Stock$476K$745K$1M$5M$0
Retained Earnings-$200M-$217M-$227M-$247M-$265M
Accumulated OCI$52M$51M$51M-$738K-$782K
Total Stockholders Equity$6M$2M-$229K$22M$28M
Total Liabilities & Equity$12M$14M$4M$51M$48M
— Key Metrics —
Total Debt$0$0$0$3M$754K
Net Debt-$9M-$13M-$4M$661K-$4M
Total Investments$0$0$0$0$0

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms